Overview

The Repatriation Medical Authority Instrument No. 125 of 2011 amends the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, specifically addressing ischaemic heart disease by modifying the Statement of Principles concerning the condition. This legislative instrument was enacted to refine the criteria for assessing ischaemic heart disease in veterans, responding to submissions received during the Authority's investigation. The Authority's decision follows the advertisement of its intent to investigate ischaemic heart disease in the Government Notices Gazette of 23 March 2011, with submissions invited from relevant parties including the Repatriation Commission and organisations representing veterans and service personnel. The instrument seeks to ensure that the assessment of ischaemic heart disease among veterans is based on the most current and relevant medical understanding, thereby addressing any legislative gaps in the recognition and treatment of this condition within the veteran community.

Scope and Application

This legislative instrument pertains to amendments made to the Veterans’ Entitlements Act 1986 by the Repatriation Medical Authority, specifically addressing ischaemic heart disease in the context of veterans’ medical entitlements. This instrument amends the Statement of Principles Instrument No. 89 of 2007, which has been previously modified by Instruments No. 43 of 2009 and No. 96 of 2010. The primary change involves the replacement of factors 6(u) and 6(qq) concerning the 'non-steroidal anti-inflammatory class of drugs'. The amendments are effective as per the provisions of the Legislative Instruments Act 2003, with a specific date of effect outlined in the instrument. The instrument applies to entities and individuals involved in the administration and adjudication of veterans' medical entitlements, particularly those dealing with ischaemic heart disease claims. Geographically, the instrument operates under the Commonwealth jurisdiction, impacting veterans across Australia. There are no exclusions or exemptions specified within the instrument, and its scope is limited to the specified factors within the Statement of Principles concerning ischaemic heart disease. The Authority may extend or restrict the application of this instrument through subordinate instruments, as necessary.

Key Provisions

The main operative sections of the Repatriation Medical Authority Instrument No. 125 of 2011 concern amendments to Statement of Principles Instrument No. 89 of 2007, specifically targeting ischaemic heart disease. Under section 196B(2) and (8) of the Veterans’ Entitlements Act 1986 (VEA), the Authority replaces factors 6(u) and 6(qq) which pertain to the 'non-steroidal anti-inflammatory class of drugs'. This revision is aimed at updating the criteria for assessing ischaemic heart disease related to the specified drug class. The obligations imposed by this Instrument on the parties it governs primarily involve the Repatriation Medical Authority and the organisations or individuals involved in the assessment and compensation of veterans’ claims. The Authority is required to investigate and amend existing Statements of Principles to ensure they reflect the most current medical understanding and evidence. The Repatriation Commission, veteran and service personnel organisations, and experts in the field are expected to provide submissions and expertise during these investigations. Additionally, the Authority must ensure that any person or organisation with an interest in the matter, as specified in section 196E(1)(a) to (c) of the VEA, can access the relevant references and information supporting the changes. The Instrument also outlines the consequences for breaches of its provisions. While the document does not explicitly detail offences, penalties, or specific consequences for non-compliance, the legislative framework within which it operates provides a basis for potential actions. Under the VEA and the Legislative Instruments Act 2003, failure to adhere to the amended Statement of Principles could lead to legal challenges or disputes regarding the assessment and compensation of ischaemic heart disease claims. These challenges may involve civil litigation where the validity or interpretation of the amended criteria could be contested. Furthermore, any procedural missteps by the Authority in determining or publicising the Instrument could result in administrative penalties or reviews under the relevant Acts. The precise penalties would depend on the nature and severity of the breach, but could include financial penalties or corrective actions mandated by a court or administrative tribunal.